Biomind Labs Inc. (BMND.NE) | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Home
Companies
Biomind Labs Inc.

BRIEF

published on 11/21/2024 at 00:30, 9 hours 26 minutes ago

Biomind Labs Sees Opportunity in U.S. Policy Shift for Psychedelic Therapies

FDA Approval Psychedelic Therapies Neurological Disorders BMND08 Drug U.S. Policy Shift
BRIEF

published on 11/21/2024 at 00:30, 9 hours 26 minutes ago

Biomind Labs voit une opportunité dans le changement de politique américaine en matière de thérapies psychédéliques

Approbation De La FDA Troubles Neurologiques Thérapies Psychédéliques Médicament BMND08 Changement De Politique Aux États-Unis
PRESS RELEASE

published on 11/21/2024 at 00:25, 9 hours 31 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Biomind Labs Inc., a leading biotech company, optimistic about U.S. government's stance on psychedelic industry. Company's BMND08 shows promising results in Phase II trial for neuropsychiatric disorders

FDA Neuropsychiatric Disorders Biomind Labs Inc. BMND08 Psychedelic Industry
BRIEF

published on 07/18/2024 at 14:35, 4 months 2 days ago

Biomind Labs Advances New Obesity Treatment with BMND06 Candidate Targeting Neurological Pathways

Obesity Treatment Clinical Trial Biomind Labs BMND06 Anti-inflammatory
BRIEF

published on 07/18/2024 at 14:35, 4 months 2 days ago

Biomind Labs fait progresser un nouveau traitement contre l'obésité avec le candidat BMND06 ciblant les voies neurologiques

Essai Clinique Traitement De L'obésité BMND06 Laboratoires Bioesprit Anti-inflammatoire
PRESS RELEASE

published on 07/18/2024 at 14:30, 4 months 2 days ago

Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Biomind Labs announced the decision to advance a Phase II clinical trial for BMND06, a novel compound with potential anti-inflammatory properties for treating obesity and neurological disorders

Phase II Trial Obesity Biomind Labs BMND06 Anti-inflammatory

Accesswire

Published on 11/21/2024 at 09:00, 56 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 21 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 31 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 56 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 56 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 15 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 55 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 56 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 56 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 41 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 58 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 58 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 58 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 48 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 36 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE